VTRS - NASDAQ

Viatris Inc.

VTRS·NASDAQ

$15.56

-0.83%

HealthcareDrug Manufacturers - Specialty & Generic

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$18.12B

EPS-3.0000

P/E Ratio-5.19

Earnings Date08/06/2026

37.19B

Assets

-10%

3Y-26.0%

5Y-40.0%

10Y+7.0%

22.48B

Total Liabilities

-2%

3Y-22.0%

5Y-42.0%

10Y-5.0%

14.71B

Total Equity

-21%

3Y-30.0%

5Y-36.0%

10Y+32.0%

Viatris Inc. Funding & Solvency Profile

VTRS · NASDAQ

Current Assets

Cash & Cash Equivalents1.35B

Net Receivables3.35B

Inventory4.00B

Other Current Assets194.80M

Total Current Assets9 B

Non-Current Assets

Property, Plant & Equipment2.89B

Goodwill & Intangible Assets21.86B

Long-Term Investments815.00M

Other Non-Current Assets1.35B

Total Non-Current Assets5 B

Total Assets

37.19B

Financial Health Analysis

Current Ratio

1.30x

Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.

Debt-to-Equity Ratio

1.53x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

2 B

Positive working capital, but relatively tight. The company should monitor cash flow carefully.

Asset Composition

25% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Viatris Inc. Balance Sheet

VTRS • NASDAQ

Viatris Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Mar 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	1.3B	734.8M	991.9M	1.3B	701.2M	844.4M	475.6M	388.1M	292.1M	998.8M	1.2B	225.5M	291.3M	350M	384.3M	686M	428.5M	597.5M	484.2M	150.1M
Short-Term Investments	106.4M	355.1M	192.5M	212.6M	233.8M	203.5M	109.1M	57.5M	110.6M	83.8M	54M	28.2M	27M	0.0	30.7M	29.1M	27.6M	42.3M	91.4M	368M
Cash & Short-Term Investments	1.5B	1.1B	1.2B	1.5B	935M	1B	584.7M	449.2M	418.9M	1.1B	1.3B	284.1M	408.6M	350M	415M	715.1M	456M	639.7M	575.6M	518.1M
Net Receivables	3.3B	3.5B	4B	4.1B	4.3B	4.8B	3.1B	2.4B	3.2B	3B	2.4B	2.3B	1.8B	1.6B	1.4B	1.2B	1.2B	1.2B	1.1B	242.2M
Accounts Receivables	2.6B	2.7B	2.8B	3.2B	3.8B	3.9B	2.6B	2.4B	3.2B	3B	2.4B	2.3B	1.8B	1.6B	1.4B	1.2B	1.2B	1.2B	1.1B	242.2M
Other Receivables	769.5M	846.7M	1.2B	899.1M	492M	952.5M	418.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	4B	3.9B	3.5B	3.5B	4B	5.5B	2.7B	2.6B	2.5B	2.5B	2B	1.7B	1.7B	1.5B	1.4B	1.2B	1.1B	1.1B	1.1B	279M
Prepaids	225.4M	140.9M	155.9M	194.6M	256.7M	267.8M	156.7M	130.6M	127.9M	169.1M	137.3M	2.3B	199.7M	243.8M	167.7M	188.3M	231.6M	105.1M	95.7M	14.9M
Other Current Assets	194.8M	913.8M	4.1B	1.3B	1.5B	1.2B	286.2M	791.2M	958.8M	743.2M	601.3M	0.0	386M	229.3M	202.9M	282.7M	296.9M	239.6M	192.1M	137.7M
Total Current Assets	9.2B	9.5B	13B	10.6B	10.9B	12.9B	6.8B	6.4B	7.2B	7.5B	6.5B	6.4B	4.5B	3.9B	3.6B	3.6B	3.3B	3.2B	3.1B	1.2B
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	2.9B	2.9B	3B	3.3B	3.5B	3.8B	2.4B	2.2B	2.3B	2.3B	2B	1.8B	1.7B	1.4B	1.3B	1.2B	1.1B	1.1B	1.1B	406.9M
Goodwill	6.8B	9.1B	9.9B	10.4B	12.1B	12.3B	9.6B	9.7B	10.2B	9.2B	5.4B	4B	4.3B	3.5B	3.5B	3.6B	3.3B	3.2B	3.9B	102.6M
Intangible Assets	15.1B	17.1B	19.2B	22.6B	26.1B	29.7B	11.6B	13.7B	15.2B	14.4B	7.2B	2.3B	2.5B	2.2B	2.6B	2.5B	2.4B	2.5B	3B	105.6M
Goodwill & Intangible Assets	21.9B	26.2B	29B	33B	38.2B	42B	21.2B	23.4B	25.5B	23.7B	12.6B	6.4B	6.9B	5.7B	6.1B	6.1B	5.7B	5.6B	6.8B	208.2M
Long-Term Investments	815M	1.3B	1.1B	1.1B	81.4M	47.9M	92.2M	138.7M	226M	396.4M	475.5M	547.4M	494.8M	0.0	0.0	0.0	0.0	0.0	0.0	462K
Tax Assets	1.1B	753M	692.9M	925.9M	1.3B	2.1B	703.1M	572.2M	496.8M	633.2M	457.6M	83.4M	77.8M	87.7M	39.4M	58.3M	36.6M	16.5M	18.7M	0.0
Other Non-Current Assets	1.4B	754M	821.1M	1.1B	798.5M	676M	58.2M	73.7M	79.6M	172.2M	276M	566.4M	1.7B	804.2M	543.2M	609.3M	641M	523.5M	337.6M	63.1M
Total Non-Current Assets	28B	32B	34.7B	39.4B	43.9B	48.7B	24.5B	26.4B	28.6B	27.2B	15.8B	9.4B	10.8B	8B	8B	8B	7.5B	7.2B	8.3B	678.6M
Total Assets	37.2B	41.5B	47.7B	50B	54.8B	61.6B	31.3B	32.7B	35.8B	34.7B	22.3B	15.8B	15.3B	11.9B	11.6B	11.5B	10.8B	10.4B	11.4B	1.9B
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.4B	2B	2.2B	2.1B	1.9B	2.2B	1.7B	1.2B	1.6B	1.4B	1.2B	905.6M	1.1B	811.6M	747.3M	582.3M	589.4M	592.9M	777.6M	76.9M
Accounts Payable	1.3B	1.4B	1.4B	1.2B	1.1B	1.3B	1.1B	1.2B	1.5B	1.3B	1.1B	905.6M	1.1B	777.9M	703.2M	564.7M	518.3M	498.8M	643.9M	76.9M
Other Payables	124M	691.1M	783.6M	910.7M	838.2M	847.1M	679.2M	0.0	112.9M	97.7M	92.4M	0.0	0.0	33.7M	44.1M	17.6M	71.1M	94.1M	133.7M	0.0
Accrued Expenses	756.4M	2.3B	2.2B	2.1B	3.1B	2.6B	1.5B	399.7M	404.6M	409.8M	367.9M	1B	784.2M	664.2M	221.5M	186M	188.7M	181.3M	0.0	0.0
Short Term Debt	2B	600K	1.9B	1.3B	3.4B	3.4B	1.5B	657.1M	1.8B	269.7M	1B	2.8B	455.6M	397M	817.2M	167.3M	190.7M	154.5M	549.7M	4.3M
Capital Lease Obligations (Current)	0.0	87.1M	83M	80.6M	86.7M	92.9M	76.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	192.7M	226.8M	279.6M	236.9M	288.6M	213M	121.5M	112.9M	97.7M	92.4M	160.9M	50.5M	35M	44.1M	17.6M	71.1M	94.1M	133.7M	13M
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2B	1.5B	2B	1.2B	1B	784.2M	301.7M	265.6M	203.5M	259.9M	275.4M	133.7M	37.3M
Other Current Liabilities	2.9B	1.3B	1.4B	1.2B	1.4B	2.2B	832.8M	2.3B	2.6B	2.9B	1.6B	604.1M	651.4M	320.6M	777.2M	874.1M	749.3M	615.9M	541.3M	146.8M
Total Current Liabilities	7.1B	5.8B	7.8B	6.7B	9.9B	10.6B	5.6B	4.6B	6.4B	5B	4.1B	5.3B	3B	2.2B	2.6B	1.8B	1.7B	1.5B	2B	265.3M
NON-CURRENT LIABILITIES
Long Term Debt	12.5B	14B	16.2B	18B	19.7B	22.4B	11.2B	13.2B	12.9B	15.2B	6.3B	5.7B	7.6B	5.3B	4.5B	5.3B	5B	5.1B	4.7B	685.2M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.7B	-2B	-2B	-718.1M	-235.4M	-468.5M	0.0	0.0	0.0	0.0	18M	122.9M	89.4M
Deferred Tax Liabilities (Non-Current)	892M	1.1B	1.7B	2.4B	2.8B	3.1B	1.6B	1.7B	2B	2B	718.1M	235.4M	468.5M	274.3M	308.9M	478.1M	467.5M	577.4M	876.8M	20.6M
Other Non-Current Liabilities	1.8B	1.8B	1.4B	1.6B	1.7B	2.3B	785.1M	1.1B	1.2B	1.4B	1.4B	1.5B	1.8B	0.0	742.2M	370.3M	485.9M	387.5M	206.7M	22.4M
Total Non-Current Liabilities	15.4B	17.1B	19.4B	22.2B	24.5B	28B	13.8B	16B	16.1B	18.6B	8.4B	7.2B	9.4B	6.4B	5.5B	6.1B	5.9B	6.1B	5.9B	817.6M
Capital Lease Obligations	178.1M	266.4M	248.4M	262M	287.6M	322.4M	252.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	22.5B	22.9B	27.2B	28.9B	34.4B	38.6B	19.4B	20.6B	22.5B	23.6B	12.5B	12.5B	12.3B	8.6B	8.1B	7.9B	7.7B	7.6B	7.9B	1.1B
SHAREHOLDERS' EQUITY
Treasury Stock	-1B	-504.3M	-251.8M	0.0	0.0	0.0	-999.7M	-999.7M	-567.7M	-67.5M	-67.5M	-3.9B	-3.9B	-2.9B	-1.9B	-1.6B	-1.6B	-1.6B	-1.6B	-1.7B
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.6B	8B	0.0	0.0	0.0	224.8M	0.0	0.0	0.0	1.1M	1.1M	1.1M	0.0
Common Stock	12.5M	12.3M	12.2M	12.1M	12.1M	12.1M	6.1M	6M	6M	6M	5.5M	273.3M	272M	269.8M	265.2M	262.9M	198.3M	197.7M	197.6M	154.6M
Additional Paid-In Capital	18.8B	18.9B	18.8B	18.6B	18.5B	18.4B	8.6B	8.6B	8.6B	8.5B	7.1B	4.2B	4.1B	4B	3.8B	3.8B	3.8B	3.9B	3.8B	419M
Retained Earnings	-388.3M	3.4B	4.6B	5.2B	3.7B	5.4B	6B	6B	5.6B	4.9B	4.5B	3.6B	2.7B	2.1B	1.4B	883.7M	660.1M	566.6M	922.9M	1.9B
Accumulated Other Comprehensive Income/Loss	-2.7B	-3.2B	-2.7B	-2.8B	-1.7B	-858M	-1.8B	-1.4B	-361.2M	-2.3B	-1.8B	-987M	-240.1M	-86.5M	-87.8M	171.9M	11.8M	-844.6M	2.2B	2.5M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1B	0.0	0.0
Total Stockholders' Equity	14.7B	18.6B	20.5B	21.1B	20.5B	23B	11.9B	12.2B	13.3B	11.1B	9.8B	3.3B	2.9B	3.3B	3.5B	3.6B	3.1B	2.8B	3.4B	787.7M
Total Equity	14.7B	18.6B	20.5B	21.1B	20.5B	23B	11.9B	12.2B	13.3B	11.1B	9.8B	3.3B	3B	3.4B	3.5B	3.6B	3.1B	2.8B	3.4B	787.7M
Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4M	1.4M	20.1M	18.1M	15.1M	13M	13.5M	14.1M	29.1M	34.3M	0.0
SUMMARY
Total Liabilities & Equity	37.2B	41.5B	47.7B	50B	54.8B	61.6B	31.3B	32.7B	35.8B	34.7B	22.3B	15.8B	15.3B	11.9B	11.6B	11.5B	10.8B	10.4B	11.4B	1.9B
Total Investments	921.4M	1.7B	1.3B	1.3B	315.2M	251.4M	201.3M	196.2M	336.6M	480.2M	529.5M	575.6M	521.8M	0.0	30.7M	29.1M	27.6M	42.3M	91.4M	368.5M
Total Debt	14.7B	14.3B	18.4B	19.5B	23.4B	26.2B	12.9B	13.8B	14.7B	15.5B	7.3B	8.5B	8B	5.7B	5.3B	5.4B	5.2B	5.2B	5.3B	689.5M
Net Debt	13.4B	13.6B	17.4B	18.3B	22.7B	25.3B	12.4B	13.4B	14.4B	14.5B	6.1B	8.3B	7.8B	5.4B	4.9B	4.7B	4.7B	4.6B	4.8B	539.4M
Shares Outstanding	1,151,769,872	1,151,769,872	1,151,769,872	1,151,769,872	1,151,769,872	1,151,769,872	1,151,769,872	1,151,769,872	1,151,769,872	1,151,769,872	1,151,769,872	1,151,769,872	1,151,769,872	1,151,769,872	1,151,769,872	1,151,769,872	1,151,769,872	1,151,769,872	1,151,769,872	1,151,769,872

SEC Filings

VTRS - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 15, 2026	May 15, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	May 01, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 02, 2026	May 15, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 23, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 03, 2026	January 29, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 08, 2025	December 08, 2025	2025	View Filing
8-K/A 8-K/A 2025 (Amended) N/A	December 05, 2025	August 04, 2025	2025	View Filing

Showing 1 to 10 of 110 filings

Related Guides

Blog Categories

Continue your VTRS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.